[Effects of novel antiviral agents on HIV-1 replication].
Two groups of the antiviral agents: 1) adamantane- and norbornen-containing compounds with in-built cholesterol to potentiate the membranotropic properties and 2) synthetic matrix protein peptides (peptides A and B) were found to have effects on HIV replication. The agents of the former group produced antiviral activity only when added in combination with the virus. Peptide A (matrix protein 43-60 amino acids) inhibited viral replication when added in both the early and late periods. Fluorescein-labeled peptide A was detectable in the cytoplasm and nucleus (although adsorption of a portion of the peptides cannot be excluded onto the cell surface). Peptide A was shown to inhibit Gag precursor p55 transport from the nuclei to the plasma membrane, the site of virus assembly. Peptide B had no antiviral activity.
Vorkunova
G K
GK
Kalnina
L B
LB
Burshteĭn
M E
ME
Serbin
A V
AV
Rodionov
I L
IL
Pavlova
M V
MV
Bukrinskaia
A G
AG
D000218:Adamantane / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009636:Norbornanes / Q000494:pharmacology*; D015688:Oncogene Protein pp60(v-src) / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D011498:Protein Precursors / Q000037:antagonists & inhibitors / Q000378:metabolism; D021381:Protein Transport / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects*
D019380:Anti-HIV Agents; D009636:Norbornanes; D010446:Peptide Fragments; D011498:Protein Precursors; C059767:p55 gag precursor protein, Human immunodeficiency virus 1; C098708:peptide A; D015688:Oncogene Protein pp60(v-src); D000218:Adamantane